Stephen K. Brannan, MD

Stephen K. Brannan, MD is a neuroscience drug development expert with more than 25 years of clinical development experience in CNS disorders. He most recently served as Chief Medical Officer of Karuna Therapeutics from 2017 until 2024, overseeing clinical development of KarXT (xanomeline and trospium) through Phase 3 trials in schizophrenia, the program that led to the approval of Cobenfy®. Earlier in his career, he held clinical and medical leadership roles at Forum Pharmaceuticals, Takeda, Novartis, Cyberonics (now LivaNova) and Eli Lilly, and has been active in the development of multiple CNS treatments, including Cymbalta, Exelon Patch, Trintellix and VNS for treatment-resistant depression. Dr. Brannan also serves on the board of directors of Serina Therapeutics, Inc. He is board-certified in psychiatry and received his AB from Harvard University and his MD from The University of Texas Southwestern Medical School.